NLS Pharma & Kadimastem File F-4 for Merger
Ticker: NCEL · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, filing, registration-statement
TL;DR
NLS Pharma filed F-4 with SEC for Kadimastem merger. Big step!
AI Summary
On December 30, 2024, NLS Pharmaceutics Ltd. announced the filing of an F-4 registration statement with the SEC. This filing is in anticipation of a proposed merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. The press release detailing this event is furnished as Exhibit 99.1.
Why It Matters
The filing of the F-4 registration statement is a significant step towards the completion of the proposed merger, potentially impacting the future structure and operations of NLS Pharmaceutics Ltd.
Risk Assessment
Risk Level: medium — Merger processes carry inherent risks, including regulatory hurdles, shareholder approval, and integration challenges, which could affect the outcome.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant and party to merger
- Kadimastem Ltd. (company) — Party to proposed merger
- December 30, 2024 (date) — Date of press release and filing
- F-4 registration statement (document) — Filed with the SEC for merger approval
- SEC (company) — Regulatory body where F-4 was filed
FAQ
What is the purpose of the F-4 registration statement filed by NLS Pharmaceutics Ltd.?
The F-4 registration statement was filed with the SEC in anticipation of a proposed merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd.
Who are the two companies involved in the proposed merger announced on December 30, 2024?
The two companies involved are NLS Pharmaceutics Ltd. and Kadimastem Ltd.
What exhibit number contains the press release about the F-4 filing?
The press release is furnished as Exhibit 99.1.
What is the filing date mentioned in the 6-K report?
The filing date is December 30, 2024.
Under which act is this Form 6-K filed?
This Form 6-K is filed under the Securities Exchange Act of 1934.
Filing Stats: 220 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-12-30 08:52:04
Filing Documents
- ea0226253-6k_nlspharma.htm (6-K) — 10KB
- ea022625301ex99-1_nlspharm.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-113270.txt ( ) — 39KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: December 30, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2